{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:35:03Z","timestamp":1793504103094,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"DOI":"10.1186\/s12886-025-04474-1","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T11:40:42Z","timestamp":1764330042000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Persistence with topical glaucoma therapy in Japan from the perspective of product, formulation, and patient characteristics: analysis of medical insurance claim data"],"prefix":"10.1186","volume":"25","author":[{"given":"Kenji","family":"Kabeya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuyo","family":"Yanagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasufumi","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"issue":"1","key":"4474_CR1","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s10384-018-0623-4","volume":"63","author":"Y Morizane","year":"2018","unstructured":"Morizane Y, Morimoto N, Fujiwara A, et al. Incidence and causes of visual impairment in japan: the first nation-wide complete enumeration survey of newly certified visually impaired individuals. Jpn J Ophthalmol. 2018;63(1):26\u201333. https:\/\/doi.org\/10.1007\/s10384-018-0623-4.","journal-title":"Jpn J Ophthalmol"},{"issue":"6","key":"4474_CR2","first-page":"SupplementalMat","volume":"80","author":"Japan Ophthalmologists Association","year":"2009","unstructured":"Japan Ophthalmologists Association. Social cost of vision impairment in Japan. J Japan Ophthalmologists Association. 2009;80(6):SupplementalMaterial.","journal-title":"J Japan Ophthalmologists Association"},{"key":"4474_CR3","unstructured":"Japan Glaucoma Society. Glaucoma Treatment Guideline 5th edition. 2022. https:\/\/www.nichigan.or.jp\/Portals\/0\/resources\/member\/guideline\/glaucoma5th%20(2).pdf. Accessed 12 Dec 2024."},{"issue":"Supplement 1","key":"4474_CR4","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1016\/j.survophthal.2008.08.002","volume":"53","author":"GF Schwartz","year":"2008","unstructured":"Schwartz GF, Quigley HA. Adherence and persistence with glaucoma therapy. Surv Ophthalmol. 2008;53(Supplement 1):S57\u201368. https:\/\/doi.org\/10.1016\/j.survophthal.2008.08.002.","journal-title":"Surv Ophthalmol"},{"issue":"1","key":"4474_CR5","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s10384-013-0284-2","volume":"58","author":"K Kashiwagi","year":"2014","unstructured":"Kashiwagi K, Furuya T. Persistence with topical glaucoma therapy among newly diagnosed Japanese patients. Jpn J Ophthalmol. 2014;58(1):68\u201374. https:\/\/doi.org\/10.1007\/s10384-013-0284-2.","journal-title":"Jpn J Ophthalmol"},{"key":"4474_CR6","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12886-020-01508-8","volume":"20","author":"K Kashiwagi","year":"2020","unstructured":"Kashiwagi K, Chono E, Koesters S, et al. Persistence and treatment patterns of fixed combination drugs for glaucoma: a retrospective claims database study in Japan. BMC Ophthalmol. 2020;20:223. https:\/\/doi.org\/10.1186\/s12886-020-01508-8.","journal-title":"BMC Ophthalmol"},{"issue":"8","key":"4474_CR7","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/j.ophtha.2007.11.023","volume":"115","author":"DS Friedman","year":"2008","unstructured":"Friedman DS, Hahn SR, Gelb L, et al. Doctor\u2013Patient Communication, Health-Related Beliefs, and adherence in glaucoma. Ophthalmology. 2008;115(8):1320\u20137. https:\/\/doi.org\/10.1016\/j.ophtha.2007.11.023.","journal-title":"Ophthalmology"},{"key":"4474_CR8","unstructured":"Santen Pharmaceutical Co. Ltd.: Comfortable use for everyone. https:\/\/www.santen.com\/ja\/business\/activity\/use (2023). Accessed 12 Dec 2024."},{"key":"4474_CR9","unstructured":"Santen Pharmaceutical Co. Ltd.: Raising awareness of the importance of eyes and promoting eye care. https:\/\/www.santen.com\/ja\/sustainability\/social\/healthcare003 (2023). Accessed 12 Dec 2024."},{"issue":"8","key":"4474_CR10","doi-asserted-by":"publisher","first-page":"4106","DOI":"10.3390\/ijerph18084106","volume":"18","author":"Y Jang","year":"2021","unstructured":"Jang Y, Jee D, Lee D, et al. Medication adherence and persistence of Open-Angle glaucoma patients in korea: A retrospective study using National health insurance claims data. Int J Environ Res Public Health. 2021;18(8):4106. https:\/\/doi.org\/10.3390\/ijerph18084106.","journal-title":"Int J Environ Res Public Health"},{"issue":"5","key":"4474_CR11","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.therap.2016.02.033","volume":"71","author":"M Belhassen","year":"2016","unstructured":"Belhassen M, Laforest L, Van Ganse \u00c9. Early adherence to anti-glaucoma therapy: an observational study. Therapie. 2016;71(5):491\u20139. https:\/\/doi.org\/10.1016\/j.therap.2016.02.033.","journal-title":"Therapie"},{"issue":"12","key":"4474_CR12","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1001\/jamaophthalmol.2014.3333","volume":"132","author":"DK Hwang","year":"2014","unstructured":"Hwang DK, Liu CJL, Pu CY, et al. Persistence of topical glaucoma medication A nationwide Population-Based cohort study in Taiwan. JAMA Ophthalmol. 2014;132(12):1446\u201352. https:\/\/doi.org\/10.1001\/jamaophthalmol.2014.3333.","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"4474_CR13","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.ophtha.2006.09.025","volume":"114","author":"GF Schwartz","year":"2007","unstructured":"Schwartz GF, Platt R, Reardon G, Mychaskiw MA. Accounting for restart rates in evaluating persistence with ocular hypotensives. Ophthalmology. 2007;114(4):648\u201352. https:\/\/doi.org\/10.1016\/j.ophtha.2006.09.025.","journal-title":"Ophthalmology"},{"issue":"4","key":"4474_CR14","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1007\/s10384-023-01020-8","volume":"67","author":"K Kashiwagi","year":"2023","unstructured":"Kashiwagi K, Ouchi K, Shibasaki Y, Suginaka M. Persistence of the carteolol hydrochloride\/latanoprost fixed-combination ophthalmic solution, compared with the other \u03b2-blocker\/prostanoid FP receptor agonist fixed-combination ophthalmic solutions. Jpn J Ophthalmol. 2023;67(4):658\u201367. https:\/\/doi.org\/10.1007\/s10384-023-01020-8.","journal-title":"Jpn J Ophthalmol"},{"issue":"1","key":"4474_CR15","doi-asserted-by":"publisher","first-page":"65","DOI":"10.14843\/jpstj.71.65","volume":"71","author":"A Ochiai","year":"2011","unstructured":"Ochiai A, Iida K, Sato Y, Kato Y, Danjo K. Design of an eye drop container for Latanoprost eye drops considering its usability by patients. Archives Practical Pharm. 2011;71(1):65\u201373. https:\/\/doi.org\/10.14843\/jpstj.71.65.","journal-title":"Archives Practical Pharm"},{"issue":"7","key":"4474_CR16","doi-asserted-by":"publisher","first-page":"380","DOI":"10.5649\/jjphcs.44.380","volume":"44","author":"N Doi","year":"2018","unstructured":"Doi N, Maida C, Takahashi E, Ide M, Miyamoto E, Akiyama S. Influences of eye drop containers on the subjective usability of a High-viscosity eye drop suspension (AZORGA\u00ae combination ophthalmic suspension). J Pharm Health Care Sci. 2018;44(7):380\u201392. https:\/\/doi.org\/10.5649\/jjphcs.44.380.","journal-title":"J Pharm Health Care Sci"},{"issue":"11","key":"4474_CR17","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.11477\/mf.1410907967","volume":"56","author":"K Yoshikawa","year":"2002","unstructured":"Yoshikawa K, Yamada H. Drop volume, rigidity and required squeezing force of glaucoma ophthalmic solution containers. Japanese J Clin Ophthalmol. 2002;56(11):1587\u201393. https:\/\/doi.org\/10.11477\/mf.1410907967.","journal-title":"Japanese J Clin Ophthalmol"},{"key":"4474_CR18","doi-asserted-by":"publisher","first-page":"e000921","DOI":"10.1136\/bmjophth-2021-000921","volume":"6","author":"B Daniels","year":"2021","unstructured":"Daniels B, Healey P, Bruno C, et al. Medicine treatment of glaucoma in Australia 2012\u20132019: prevalence, incidence and persistence. BMJ Open Ophthalmol. 2021;6:e000921. https:\/\/doi.org\/10.1136\/bmjophth-2021-000921.","journal-title":"BMJ Open Ophthalmol"},{"key":"4474_CR19","unstructured":"Yoshio Yazaki. Chiryoyaku Manual 2024. Igakushoin; 2024. ISBN: 978-4-260-05359-4."},{"key":"4474_CR20","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40780-025-00434-5","volume":"11","author":"K Kabeya","year":"2025","unstructured":"Kabeya K, Satoh H, Yanagi N, Sawada Y. Bisphosphonate compliance in Japan from the perspective of product, formulation, and patient characteristics: analysis of medical insurance claim data. J Pharm Health Care Sci. 2025;11:30. https:\/\/doi.org\/10.1186\/s40780-025-00434-5.","journal-title":"J Pharm Health Care Sci"},{"issue":"2","key":"4474_CR21","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3390\/pharmacy9020090","volume":"9","author":"R Nakajima","year":"2021","unstructured":"Nakajima R, Watanabe F, Kamei M. Factors associated with medication Non-Adherence among patients with Lifestyle-Related Non-Communicable diseases. Pharmacy. 2021;9(2):90. https:\/\/doi.org\/10.3390\/pharmacy9020090.","journal-title":"Pharmacy"},{"issue":"1","key":"4474_CR22","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1186\/s12913-023-09904-8","volume":"23","author":"L Ge","year":"2023","unstructured":"Ge L, Heng BH, Yap CW. Understanding reasons and determinants of medication non-adherence in community-dwelling adults: a cross-sectional study comparing young and older age groups. BMC Health Serv Res. 2023;23(1):905. https:\/\/doi.org\/10.1186\/s12913-023-09904-8.","journal-title":"BMC Health Serv Res"},{"key":"4474_CR23","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12902-019-0360-9","volume":"19","author":"LN Aminde","year":"2019","unstructured":"Aminde LN, Tindong M, Ngwasiri CA, et al. Adherence to antidiabetic medication and factors associated with non-adherence among patients with type-2 diabetes mellitus in two regional hospitals in Cameroon. BMC Endocr Disorders. 2019;19:35. https:\/\/doi.org\/10.1186\/s12902-019-0360-9.","journal-title":"BMC Endocr Disorders"},{"key":"4474_CR24","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.oftale.2011.04.006","volume":"86","author":"M S\u00e1nchez-Pulgar\u00edn","year":"2011","unstructured":"S\u00e1nchez-Pulgar\u00edn M, Mart\u00ednez-de-la-Casa JM, Escalada A, S\u00e1enz-Franc\u00e9s J, Garc\u00eda-Feijo\u00f3 F, S\u00e1nchez JG. The influence of the Travalert\u00ae dosing aid on medical treatment compliance and the quality of life of glaucoma patients. Arch De La Sociedad Espa\u00f1ola De Oftalmolog\u00eda. 2011;86:282\u20136. https:\/\/doi.org\/10.1016\/j.oftale.2011.04.006.","journal-title":"Arch De La Sociedad Espa\u00f1ola De Oftalmolog\u00eda"},{"issue":"2","key":"4474_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.11204\/ithc.12.9","volume":"12","author":"N Ito","year":"2017","unstructured":"Ito N, Yamamoto E, Iwazaki T, Kumazawa M, Kanno N. Investigation of the effect of our medication reminder alarm as a smartphone application for medication adherence. Japanese J Appl IT Healthc. 2017;12(2):9\u201318. https:\/\/doi.org\/10.11204\/ithc.12.9.","journal-title":"Japanese J Appl IT Healthc"},{"issue":"8","key":"4474_CR26","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1097\/IJG.0b013e3181f3eb4a","volume":"20","author":"MM Hermann","year":"2011","unstructured":"Hermann MM, Bron AM, Creuzot-Garcher CP, Diestelhorst M. Measurement of adherence to brimonidine therapy for glaucoma using electronic monitoring. J Glaucoma. 2011;20(8):502\u20138. https:\/\/doi.org\/10.1097\/IJG.0b013e3181f3eb4a.","journal-title":"J Glaucoma"},{"issue":"5","key":"4474_CR27","doi-asserted-by":"publisher","first-page":"441","DOI":"10.2147\/PPA.S23780","volume":"23","author":"G Reardon","year":"2011","unstructured":"Reardon G, Kotak S, Schwartz GF. Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review. Patient Prefer Adherence. 2011;23(5):441\u201363. https:\/\/doi.org\/10.2147\/PPA.S23780.","journal-title":"Patient Prefer Adherence"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-025-04474-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-025-04474-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-025-04474-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T00:03:26Z","timestamp":1764374606000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-025-04474-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4474"],"URL":"https:\/\/doi.org\/10.1186\/s12886-025-04474-1","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"16 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable, as JMDC Inc. ensured that the data was sufficiently anonymized and formal consent was not considered required for this retrospective study. This study was approved by Research Ethics Committee of the Faculty of Pharmaceutical Sciences of the University of Tokyo (approval number: 6\u201311), in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable, as JMDC Inc. ensured that the data was sufficiently anonymized.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HS, NY, and YS were the members of an endowed laboratory funded by companies including Ain Pharmaciez Inc., I & H Co., Ltd., Medical Ikkou Co., Ltd., Toho Holdings Co., Ltd., Tomod\u2019s, and Wakaba Co. until March 2025. The companies were not directly involved in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"676"}}